이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Naoxintong Capsule for Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled TrialAcronymNXT-DKD (NXT-DKD)

2026년 7월 8일 업데이트: Chen Xiangmei

Evidence-Based Evaluation of Naoxintong Capsule in the Treatment of Diabetic Nephropathy With Dampness Retention Pattern: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Diabetic nephropathy (DN) is a leading cause of end-stage kidney disease worldwide and is associated with a high risk of cardiovascular events and mortality. Despite current standard therapies including renin-angiotensin system inhibitors (ACEI/ARB), glycemic control, and blood pressure management, disease progression remains inadequately controlled in many patients.

Naoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal ingredients (Astragalus membranaceus, Prunus persica seed, Carthamus tinctorius, Paeonia lactiflora, Angelica sinensis, Ligusticum chuanxiong, Boswellia carterii, Commiphora myrrha, Salvia miltiorrhiza, Achyranthes bidentata, Cinnamomum cassia, Morus alba, Spatholobus suberectus, Buthus martensii, Pheretima aspergillum, and Hirudo nipponica). It has been widely used in China for cardiovascular and cerebrovascular diseases, with demonstrated effects on endothelial protection, anti-inflammation, anti-thrombosis, and plaque stabilization.

This multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy and safety of Naoxintong Capsule added to standard conventional therapy in slowing the progression of diabetic nephropathy and providing cardiovascular protection. A total of 410 patients with Type 2 diabetic nephropathy will be randomized (1:1) to receive either Naoxintong Capsules (4 capsules, 3 times daily) or matching placebo, in addition to standard therapy, for 12 months. The primary outcome is the annual rate of decline in estimated glomerular filtration rate (eGFR). Secondary outcomes include changes in proteinuria, CKD stage progression, time to end-stage kidney disease, major adverse cardiovascular events, TCM syndrome scores, and quality of life measures.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

BACKGROUND AND RATIONALE

Diabetic nephropathy (DN) is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in economically developed countries. China has the largest diabetic population globally, and DN now accounts for approximately 30% of new dialysis patients. Despite the beneficial effects of ACE inhibitors (ACEI) and Angiotensin II receptor blockers (ARB) in the microalbuminuric stage, landmark trials (RENNAL, IDNT, VA NEPHRON-D) have shown that these agents alone or in combination fail to significantly reduce cardiovascular events and all-cause mortality in advanced DN. There is an urgent need for novel therapeutic approaches to slow DN progression and improve survival.

Naoxintong Capsule (National Drug Approval No.: Guoyaozhunzi Z20025001) is a well-established traditional Chinese medicine formulation that has been widely used in China for cardiovascular and cerebrovascular diseases. It comprises 16 herbal and animal-derived ingredients that collectively exert effects through endothelial protection, anti-inflammatory activity, inhibition of thrombosis, and plaque stabilization. Based on the integrative medicine concept of brain-heart-kidney co-treatment and the shared pathophysiological mechanisms underlying DN progression and cardiovascular complications, Naoxintong Capsule represents a promising adjunctive therapy for DN.

STUDY DESIGN AND OBJECTIVES

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial designed to provide high-level evidence for the efficacy and safety of Naoxintong Capsule in treating DN. The study will enroll 410 adult patients with confirmed Type 2 diabetic nephropathy across approximately 20 clinical centers in China.

The primary objective is to evaluate whether adding Naoxintong Capsule to standard conventional therapy can slow the annual rate of eGFR decline compared with standard therapy alone (with placebo). Secondary objectives include assessing effects on proteinuria, CKD stage progression, time to ESKD, cardiovascular events, traditional Chinese medicine (TCM) syndrome scores, and health-related quality of life.

PARTICIPANT POPULATION

Eligible participants are adults (age >= 18 years) with confirmed Type 2 diabetic nephropathy, 24-hour urinary protein excretion between 0.5 and 3.5 g, eGFR >= 45 mL/min/1.73m2, and on stable ACEI/ARB therapy for at least 8 weeks prior to enrollment. Patients must discontinue all other traditional Chinese medicine products for a washout period of at least 4 weeks before randomization.

INTERVENTION

Participants will be randomized (1:1) to receive either Naoxintong Capsules or matching placebo capsules, both administered as 4 capsules per dose, 3 times daily, taken orally 30 to 60 minutes after meals. All participants continue to receive standard conventional therapy for DN, including glycemic control, blood pressure management, lipid-lowering therapy, dietary management, and treatment of CKD-related complications as clinically indicated. The treatment duration is 12 months.

FOLLOW-UP AND ASSESSMENTS

Following randomization at Visit 1 (V1), participants will attend scheduled visits at Month 1 (V2), Month 3 (V3), Month 6 (V4), Month 9 (V5), and Month 12 (V6). At each visit, clinical assessments include physical examination, laboratory tests (urinalysis, 24-hour urine protein, urine albumin-to-creatinine ratio, complete blood count, blood biochemistry including renal function, HbA1c, lipid profile, hs-CRP, IL-6), ECG, TCM syndrome scoring, and adverse event monitoring. At selected visits (V1, V6), additional imaging studies (chest X-ray/CT, renal ultrasound) and optional fundoscopy are performed. Biological samples (blood, urine, stool) are collected at V1, V4, and V6 for exploratory analyses including gut microbiota and metabolomics.

SAMPLE SIZE

The sample size of 410 (205 per group) was calculated based on detecting a clinically meaningful difference of 1.0 mL/min/1.73m2/year in eGFR annual decline slope between groups (expected: -3.0 vs. -2.0 mL/min/1.73m2/year), with a pooled standard deviation of 3.2, at a two-sided alpha of 0.05 and 80% power, allowing for a 20% dropout rate.

STATISTICAL ANALYSIS

Efficacy analyses will be conducted on both the Full Analysis Set (FAS, intention-to-treat) and the Per-Protocol Set (PPS). The primary analysis will use a mixed-effects model for the eGFR slope, adjusting for center effect. Time-to-event outcomes will be analyzed using Kaplan-Meier methods and Cox proportional hazards models. Safety analyses will be performed on the FAS.

연구 유형

중재적

등록 (추정된)

410

단계

  • 4단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

  • 중국
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국
        • China-Japan Friendship Hospital
        • 연락하다:
      • Beijing, Beijing Municipality, 중국, 100853
        • Chinese PLA General Hospital, First Medical Center
        • 연락하다:
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, 중국
        • Daping Hospital, Army Medical University
        • 연락하다:
    • Liaoning
      • Dalian, Liaoning, 중국
        • First Affiliated Hospital of Dalian Medical University
        • 연락하다:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국
        • Renji Hospital, Shanghai Jiao Tong University School of Medicine
        • 연락하다:
      • Shanghai, Shanghai Municipality, 중국
        • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
        • 연락하다:
      • Shanghai, Shanghai Municipality, 중국
        • Longhua Hospital, Shanghai University of Traditional Chinese Medicine
        • 연락하다:
    • Zhejiang
      • Hangzhou, Zhejiang, 중국
        • Zhejiang Provincial Hospital of Traditional Chinese Medicine
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  1. Age >= 18 years.

  2. Meets the diagnostic criteria for Type 2 diabetic nephropathy, defined as:

    1. Confirmed diagnosis of Type 2 diabetes mellitus; AND
    2. At least one of the following: urinary albumin-to-creatinine ratio (UACR) >= 30 mg/g, or eGFR < 60 mL/min/1.73m^2, confirmed by repeat testing (interval >= 3 months), after excluding transient factors such as acute kidney injury, dehydration, infection, or heart failure; OR
    3. Renal biopsy confirmed as isolated diabetic nephropathy; AND
    4. Exclusion of other primary or secondary kidney diseases.
  3. 24-hour urinary protein excretion >= 0.5 g and < 3.5 g.
  4. Estimated glomerular filtration rate (eGFR) >= 45 mL/min/1.73m^2.
  5. On a stable dose of ACE inhibitor (ACEI) or Angiotensin II receptor blocker (ARB) therapy for at least 8 weeks prior to enrollment. If SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), or GLP-1 receptor agonists are being used, the dose must have been stable for at least 4 weeks prior to enrollment and remain unchanged during the study period. Patients not currently using these agents must not initiate them during the study.
  6. Signed informed consent form.

Exclusion Criteria:

  1. Type 1 diabetes mellitus or other types of diabetes mellitus (e.g., secondary diabetes, maturity-onset diabetes of the young).
  2. Coexisting systemic autoimmune or immune-mediated disease where the clinical assessment suggests a non-diabetic nephropathy etiology.
  3. Decline in eGFR of > 30% within the past 3 months.
  4. Persistent serum potassium > 5.5 mmol/L.
  5. Diagnosis of hemorrhagic cardiovascular or cerebrovascular disease within the past 3 months.
  6. Known allergy or hypersensitivity to any component of Naoxintong Capsule or placebo; pregnant or lactating women.
  7. Participation in another drug or medical device clinical trial within the past 6 months.
  8. Any other condition that, in the investigator's judgment, renders the patient unsuitable for participation in the clinical trial (e.g., severe hepatic dysfunction, life expectancy < 1 year).

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Naoxintong Capsule Group
Participants will receive Naoxintong Capsules (4 capsules per dose, 3 times daily, orally, 30-60 minutes after meals) in addition to standard conventional therapy for diabetic nephropathy, for a total treatment duration of 12 months. Standard conventional therapy includes glycemic control (oral hypoglycemic agents and/or insulin), blood pressure management (ACEI or ARB, with optional non-RASI antihypertensives), lipid-lowering therapy (statins as indicated), dietary management (protein 0.6-0.8 g/kg/day, sodium <3 g/day), and treatment of CKD-related complications as clinically indicated.
의약품: Naoxintong Capsule
Naoxintong Capsule is a traditional Chinese medicine formulation composed of 16 herbal and animal-derived ingredients: Astragalus membranaceus (Huangqi), Prunus persica seed (Taoren), Carthamus tinctorius flower (Honghua), Paeonia lactiflora root (Chishao), Angelica sinensis root (Danggui), Ligusticum chuanxiong rhizome (Chuanxiong), Boswellia carterii resin (Ruxiang), Commiphora myrrha resin (Moyao), Salvia miltiorrhiza root (Danshen), Achyranthes bidentata root (Niuxi), Cinnamomum cassia twig (Guizhi), Morus alba twig (Sangzhi), Spatholobus suberectus stem (Jixueteng), Buthus martensii (Quanxie), Pheretima aspergillum (Dilong), and Hirudo nipponica (Shuizhi). Each capsule contains 0.4 g of active ingredients. Dosage: 4 capsules (1.6 g) per dose, taken orally 3 times daily, 30-60 minutes after meals. Manufactured by Shaanxi Buchang Pharmaceutical Co., Ltd. (National Drug Approval No.: Guoyaozhunzi Z20025001). Storage: sealed, at room temperature. Shelf life: 24 months.
위약 비교기: Placebo Group
Participants will receive matching placebo capsules (4 capsules per dose, 3 times daily, orally, 30-60 minutes after meals) in addition to standard conventional therapy for diabetic nephropathy, for a total treatment duration of 12 months. Standard conventional therapy is identical to that provided in the Naoxintong group.
의약품: Placebo
Matching placebo capsules identical in appearance, size, shape, color, weight, packaging, and labeling to Naoxintong Capsules but containing no active pharmaceutical or herbal ingredients. Dosage: 4 capsules per dose, taken orally 3 times daily, 30-60 minutes after meals. Manufactured by Shaanxi Buchang Pharmaceutical Co., Ltd. Storage: sealed, at room temperature. Shelf life: 24 months.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Annual Rate of Decline in Estimated Glomerular Filtration Rate (eGFR)
기간: Baseline to Month 12
The annual rate of decline in eGFR (ml/min/1.73m^2/year), calculated as the slope of eGFR over the 12-month treatment period using all available eGFR measurements at each scheduled visit. eGFR is estimated using the CKD-EPI equation. A less negative slope indicates slower disease progression.
Baseline to Month 12
Change in 24-Hour Urinary Protein Excretion From Baseline
기간: Baseline to Month 12
Change from baseline in 24-hour urinary protein excretion (g/24h), measured at each scheduled visit. A decrease indicates renal protective effect.
Baseline to Month 12
Renal Composite Endpoint: eGFR Decline >30%, ESKD, or MACE
기간: From randomization through Month 12
Time to first occurrence of: sustained eGFR decline >30% from baseline; end-stage kidney disease; or major adverse cardiovascular event.
From randomization through Month 12

2차 결과 측정

결과 측정
측정값 설명
기간
Proportion of Participants With CKD Stage Improvement, Stabilization, or Progression
기간: Baseline to Month 12
Proportion of participants whose CKD stage (KDIGO eGFR categories) improved, remained stable, or progressed.
Baseline to Month 12
Time to Sustained eGFR Decline of Greater Than 30% From Baseline
기간: From randomization through Month 12
Time from randomization to first confirmed sustained eGFR decline exceeding 30% from baseline.
From randomization through Month 12
Time to End-Stage Kidney Disease (ESKD)
기간: From randomization through Month 12
Time from randomization to ESKD: maintenance dialysis, kidney transplantation, or sustained eGFR <15.
From randomization through Month 12
Time to First Unplanned Hospitalization for Heart Failure
기간: From randomization through Month 12
Time from randomization to first unplanned hospital admission primarily due to heart failure.
From randomization through Month 12
Time to First Non-Fatal Myocardial Infarction
기간: From randomization through Month 12
Time from randomization to first non-fatal MI per WHO-MONICA criteria.
From randomization through Month 12
Time to First Non-Fatal Ischemic Stroke
기간: From randomization through Month 12
Time from randomization to first non-fatal ischemic stroke with imaging confirmation.
From randomization through Month 12
Time to Cardiovascular Death or Stroke-Related Death
기간: From randomization through Month 12
Time from randomization to death attributable to cardiovascular or cerebrovascular causes.
From randomization through Month 12
Time to All-Cause Death
기간: From randomization through Month 12
Time from randomization to death from any cause.
From randomization through Month 12
Change in TCM Syndrome Score From Baseline
기간: Baseline to Month 12
Change in TCM syndrome score using a standardized 90-item questionnaire.
Baseline to Month 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

Chen Xiangmei

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 3월 1일

기본 완료 (추정된)

2028년 6월 1일

연구 완료 (추정된)

2028년 12월 30일

연구 등록 날짜

최초 제출

2026년 7월 8일

QC 기준을 충족하는 최초 제출

2026년 7월 8일

처음 게시됨 (실제)

2026년 7월 13일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 7월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 8일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • NXT-DKD-2026-001

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) may be shared with qualified researchers upon reasonable request, subject to a data use agreement, following publication of the primary results.

IPD 공유 기간

After publication of primary results

IPD 공유 액세스 기준

Via reasonable request with data use agreement

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

당뇨병성 신증에 대한 임상 시험

Naoxintong Capsule에 대한 임상 시험

유사한 임상시험 검색

스폰서 및 공동 작업자

건강 상태

약물 개입

CROs by country

CROs in Panama

정황

희귀 질병

약물 개입

식이 보충제

스폰서 / 협력자

위치

3
구독하다